Modality
mAb
MOA
CAR-T BCMA
Target
SHP2
Pathway
Tau
Bladder Ca
Development Pipeline
Preclinical
~Oct 2021
→ ~Jan 2023
Phase 1
Apr 2023
→ Sep 2025
Phase 1Current
NCT04711506
445 pts·Bladder Ca
2023-04→2025-09·Not yet recruiting
445 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-09-266mo agoInterim· Bladder Ca
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P1
Not yet…
Catalysts
Interim
2025-09-26 · 6mo ago
Bladder Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04711506 | Phase 1 | Bladder Ca | Not yet recr... | 445 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 |